You are here: Industry Insights > mRNA-1273

News List

FDA fast-tracks Moderna’s Covid-19 vaccine candidate pharmaceutical-technology
May 14, 2020
The US Food and Drug Administration (FDA) has awarded fast-track designation to Moderna mRNA vaccine candidate, mRNA-1273, developed to protect against Covid-19.
Moderna signs ten-year vaccine manufacturing deal with Lonza pharmaceutical-technology
May 04, 2020
Moderna has signed a ten-year agreement with Lonza for large-scale manufacture of its vaccine candidate, mRNA-1273, against Covid-19 and other products in the future.
BARDA to give Moderna up to $483 million for COVID-19 vaccine development europeanpharmaceuticalreview
April 22, 2020
The US Biomedical Advanced Research and Development Authority (BARDA) will fund Moderna’s COVID-19 vaccine candidate mRNA-1273 through Phase II and III clinical trials to FDA licensure.
US BARDA commits up to $483m for Moderna Covid-19 vaccine pharmaceutical-technology
April 20, 2020
The US Biomedical Advanced Research and Development Authority (BARDA) has committed up to $483m to support the development of the Moderna mRNA vaccine candidate, mRNA-1273, against Covid-19.
First US clinical trial of Covid-19 vaccine candidate begins pharmaceutical-technology
March 18, 2020
The first US clinical trial of a Covid-19 vaccine candidate, which is Moderna’s mRNA-1273, has started at Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle.
First Patient Dosed in Moderna's COVID-19 Vaccine Trial biospace
March 17, 2020
Inside the U.S., the first clinical trial for a vaccine to the novel coronavirus that causes COVID-19 began.

Previous page 1 2 3 4 5 6 Next page